Study in human cells finds low-cost drug keeps virus dormant through an unexpected pathway, pointing the way to new treatments.
McGill University press release
Lithium, a widely used treatment for bipolar disorder and other mood disorders, has shown early promise in suppressing HIV, McGill University researchers report.
A new study published in iScience found lithium can prevent infected cells from reactivating, and that it does so through an unexpected biological mechanism.
The findings point toward future treatments designed to mimic lithium’s beneficial effects while avoiding its broader impacts on the body.
The results do not mean people with HIV should take lithium. The psychoactive drug can cause significant side effects and has not yet been tested in humans as an HIV treatment.
Read the full press release here.
Source : McGill University
Related HIV and Co-Infections News
-
[Press release] Weizmann Institute of Science: Gut microbes actively support immunity in people living with HIV
-
[Press release] University of Cologne: HIV antibody opens up new approaches for vaccine development and combination therapies
-
[Press release] Salk Institute: How do nature and nurture shape our immune cells?
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.